NasdaqCM:HRTXBiotechs
Heron Therapeutics (HRTX) Quarterly Loss Revives Dilution Fears And Tests Profitability Narrative
Heron Therapeutics (HRTX) opened Q1 2026 with revenue of US$34.7 million, a basic EPS loss of US$0.04 and a net loss of US$8.1 million. On a trailing twelve month basis, the company recorded revenue of US$150.7 million and a basic EPS loss of US$0.18. Over recent quarters, revenue has moved between US$34.7 million and US$40.8 million, with quarterly basic EPS ranging from a profit of US$0.02 to a loss of US$0.10. This keeps the focus firmly on how quickly margins can tighten up from here.
See...